Trastuzumab MMAE
82928

TargetERBB2
Product group Antibodies
Overview
- SupplierBPS Bioscience
- Product NameTrastuzumab MMAE
- Delivery Days Customer23
- CertificationResearch Use Only
- ClonalityMonoclonal
- Estimated Purity≥90%
- Gene ID2064
- Target nameERBB2
- Target descriptionerb-b2 receptor tyrosine kinase 2
- Target synonymsCD340; c-erb B2/neu protein; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; metastatic lymph node gene 19 protein; MLN 19; NEU; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; proto-oncogene c-ErbB-2; proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; VSCN2
- Protein IDP04626
- Protein NameReceptor tyrosine-protein kinase erbB-2
- Scientific DescriptionTrastuzumab MMAE is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab MMAE is composed of a humanized anti-HER2 antibody Trastuzumab, an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE). Trastuzumab MMAE can be used for the research of HER2-positive breast cancer1.
- Storage Instruction-80°C
- UNSPSC12352203